GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
发明人:
RAMANJULU, Joshi M.,ROMANO, Joseph J.,WANG, Gren Z.,NEVINS, Neysa,ZHANG, Daohua,HUGHES, Terry V.,LI, Yue,LIAN, Yiqian,CHARNLEY, Adam Kenneth,DONG, Xiaoyang,DARCY, Michael G.,MEHLMANN, John F.
申请号：
CR20200045
公开号：
CR20200045A
申请日:
2017.04.05
申请国别(地区):
CR
年份:
2020
代理人:
摘要：
The compounds described refer to (I-N) formula, where Q, R, s, a, B, C, ra1, ra2, Rb1, Rb2, R1, R2, R3, R4, R5, R6, R14, R15, R16, and R17 are the compounds defined in this report, or a plasma of these compounds, or a salt, especially a salt acceptable in medicine. I'm sorry Is the compound (I-N) that has been formulated,Wherein Q，R，S，A，B，C，RA1，RA2，RB1，RB2，R1，R2，R3，R4，R5，R6，R14，R15，R16，and R17，are a s defined here，or a tautmer thereof，or a salt，particularly a pharmaceutically acceptable salt，thereof.Se describen compuestos que tienen la fórmula: (I-N) en donde q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, y R17, son como se definen en la presente memoria, o un tautómero de los mismos, o una sal, en particular una sal farmacéuticamente aceptable de los mismos.Disclosed are compounds having the formula (I-N), wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, and R17, are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.
